Sonova stock rises 2.70 percent near its 52-week high

Published on 09/28/2026 at 16:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sonova stock traded at CHF 247.60 on September 28, 2026, only 0.16 percent below its 52-week high. FY 2025/26 sales rose 5.9 percent.

Professional architectural photography of a modern medical technology corporate headquarters building featuring floor-to-ceiling glass facade with structural transparency revealing bright open office floors, surrounded by manicured greenery and a reflecti — Sonova CH0012549785: Modernes Med-Tech-Headquarter mit transparenter Glasfassade, Spiegelbecken und Grünanlagen bei goldenem Abendlicht, Illustration mit AI erstellt.

Sonova stock (ISIN CH0012549785) traded at CHF 247.60 on SIX at 12:28 p.m. CET on September 28, 2026, up 2.70 percent and just 0.16 percent below its 52-week high of CHF 248.00. The move gives investors a clear market signal as the hearing-aid maker approaches its next scheduled results date.

Shares approach the yearly high

Sonova opened at CHF 242.20 and reached an intraday high of CHF 248.00 on September 28, 2026. Trading volume stood at 18,080 shares, while the 52-week low was CHF 163.00 on March 23, 2026.

The stock's position near the yearly high contrasts with the wider annual range. The current price was 34.17 percent above the 52-week low, showing that the share price has recovered substantially from its March level.

Growth supports the valuation

Sonova reported FY 2025/26 group sales of CHF 3,605.9 million, up 5.9 percent in local currencies. Hearing Instruments sales increased 7.5 percent to CHF 3.4 billion, according to the company results published for the fiscal year ended March 31, 2026.

The earnings profile was stronger than the top line. According to Yahoo Finance, normalized EBITDA rose 17.3 percent to CHF 794 million, while the normalized EBITDA margin reached 23.7 percent, up 280 basis points in local currencies.

Bernstein sets CHF 275 target

Bernstein named Sonova its short-term top European medtech pick on September 25, 2026, with an Outperform rating and a CHF 275.00 price target, as Yahoo Finance reported. The target lies 11.06 percent above the September 28 price.

Bernstein forecasts first-half wholesale organic growth of 10.1 percent versus 8.0 percent consensus, and group organic growth of 6.5 percent versus 4.9 percent consensus. Sonova's own outlook calls for consolidated sales growth of 5 percent to 8 percent and core EBIT growth of 7 percent to 10 percent at constant exchange rates.

November results set the next test

finanzen.ch lists November 12, 2026, for Sonova's Q2 2027 results. The next operating test is therefore whether new hearing-aid products and retail expansion can sustain the margin gains already visible in FY 2025/26.